{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Boehringer+Ingelheim", "query": { "sponsor": "Boehringer Ingelheim" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 662, "total_pages": 67, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Boehringer+Ingelheim&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-07T16:12:21.996Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00819091", "title": "Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "BI 1356", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 245, "start_date": "2008-12", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-06-27", "last_synced_at": "2026-06-07T16:12:21.996Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Los Angeles, California • National City, California + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "National City", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00819091" }, { "nct_id": "NCT01732796", "title": "IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Ribavirin (RBV)", "type": "DRUG" }, { "name": "BI 201335 (Faldaprevir)", "type": "DRUG" }, { "name": "BI 207127", "type": "DRUG" }, { "name": "Faldaprevir (BI 201335)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 470, "start_date": "2012-12", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2016-04-18", "last_synced_at": "2026-06-07T16:12:21.996Z", "location_count": 24, "location_summary": "Dothan, Alabama • Chula Vista, California • La Mesa, California + 19 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Chula Vista", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "Poway", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01732796" }, { "nct_id": "NCT01397162", "title": "Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Fluticasone propionate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "BI 54903", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "12 Years to 65 Years" }, "enrollment_count": 29, "start_date": "2011-07-21", "completion_date": "2011-12-23", "has_results": true, "last_update_posted_date": "2022-06-23", "last_synced_at": "2026-06-07T16:12:21.996Z", "location_count": 41, "location_summary": "Fountain Valley, California • Huntington Beach, California • Long Beach, California + 36 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Palmdale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01397162" }, { "nct_id": "NCT04975256", "title": "Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Metastatic Cancer", "Malignant Neoplasm of Colon", "Malignant Neoplasm of Lung", "Malignant Neoplastic Disease" ], "interventions": [ { "name": "MRTX849", "type": "DRUG" }, { "name": "BI 1701963", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirati Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2021-07-28", "completion_date": "2022-11-15", "has_results": false, "last_update_posted_date": "2024-12-16", "last_synced_at": "2026-06-07T16:12:21.996Z", "location_count": 4, "location_summary": "St Louis, Missouri • Cleveland, Ohio • Houston, Texas + 1 more", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04975256" }, { "nct_id": "NCT06628622", "title": "A Study to Test Whether BI 1356225 Improves Impulsive Behavior in People With Opioid Use Disorder Who Are Taking Buprenorphine", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Opioid Use Disorder" ], "interventions": [ { "name": "BI 1356225", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 60, "start_date": "2025-01-27", "completion_date": "2027-02-14", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-06-07T16:12:21.996Z", "location_count": 5, "location_summary": "Los Alamitos, California • Los Angeles, California • Decatur, Georgia + 2 more", "locations": [ { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Marlton", "state": "New Jersey" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06628622" }, { "nct_id": "NCT02008825", "title": "Evaluation of the ViSiGiTM Calibration System", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Enhance Delineation of the Stomach Anatomy and the Surgeon's Appreciation of the Extent of Gastric Volume to be Removed;", "Increase the Safety Profile of the Patient (i.e., Reduce the Likelihood of Accidental Stapling of the Orogastric Tube or Bougie);", "Reduce the Incidence of OR Contamination/Infection Transmission;", "Streamline OR Workflow, Resulting in Reduced OR Time", "Ensure Consistent and Reproducible Staple Lines." ], "interventions": [ { "name": "Utilization of ViSiGi calibration tube", "type": "DEVICE" }, { "name": "Usual non suction Bougie", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "St. Luke's Hospital and Health Network, Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2014-01", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2013-12-11", "last_synced_at": "2026-06-07T16:12:21.996Z", "location_count": 1, "location_summary": "Allentown, Pennsylvania", "locations": [ { "city": "Allentown", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02008825" }, { "nct_id": "NCT02006732", "title": "Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "olodaterol", "type": "DRUG" }, { "name": "tiotropium", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 809, "start_date": "2013-11", "completion_date": "2014-11", "has_results": true, "last_update_posted_date": "2016-01-20", "last_synced_at": "2026-06-07T16:12:21.996Z", "location_count": 20, "location_summary": "Jasper, Alabama • Stamford, Connecticut • Clearwater, Florida + 17 more", "locations": [ { "city": "Jasper", "state": "Alabama" }, { "city": "Stamford", "state": "Connecticut" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Duluth", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02006732" }, { "nct_id": "NCT06067984", "title": "An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia", "Negative Symptoms in Schizophrenia" ], "interventions": [ { "name": "Study App", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Click Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 73, "start_date": "2023-09-12", "completion_date": "2025-08-22", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-06-07T16:12:21.996Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06067984" }, { "nct_id": "NCT00748709", "title": "Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "BIBW 2992 (Afatinib)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 20, "start_date": "2008-10-01", "completion_date": null, "has_results": true, "last_update_posted_date": "2025-02-11", "last_synced_at": "2026-06-07T16:12:21.996Z", "location_count": 12, "location_summary": "Los Angeles, California • Denver, Colorado • Indianapolis, Indiana + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT00748709" }, { "nct_id": "NCT04419506", "title": "A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Idiopathic Pulmonary Fibrosis" ], "interventions": [ { "name": "BI 1015550", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 147, "start_date": "2020-07-28", "completion_date": "2021-10-15", "has_results": true, "last_update_posted_date": "2022-11-01", "last_synced_at": "2026-06-07T16:12:21.996Z", "location_count": 11, "location_summary": "Clearwater, Florida • Gainesville, Florida • Kansas City, Kansas + 8 more", "locations": [ { "city": "Clearwater", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Chesterfield", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04419506" } ] }